Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:NTLA
- CUSIP: N/A
- Web: www.intelliatx.com
- Market Cap: $629.43 million
- Outstanding Shares: 36,113,000
- 50 Day Moving Avg: $16.49
- 200 Day Moving Avg: $14.48
- 52 Week Range: $10.83 - $24.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.98
- P/E Growth: 0.00
- Annual Revenue: $22.63 million
- Price / Sales: 27.81
- Book Value: $5.20 per share
- Price / Book: 3.35
- EBIDTA: ($45,440,000.00)
- Net Margins: -204.48%
- Return on Equity: -22.70%
- Return on Assets: -16.17%
- Current Ratio: 9.33%
- Quick Ratio: 9.33%
- Average Volume: 263,569 shs.
- Beta: 2.86
- Short Ratio: 9.17
Frequently Asked Questions for Intellia Therapeutics (NASDAQ:NTLA)
What is Intellia Therapeutics' stock symbol?
Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."
How were Intellia Therapeutics' earnings last quarter?
Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, August, 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analysts' expectations of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The company's quarterly revenue was up 40.5% on a year-over-year basis. View Intellia Therapeutics' Earnings History.
Where is Intellia Therapeutics' stock going? Where will Intellia Therapeutics' stock price be in 2017?
8 brokers have issued 1 year price objectives for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $36.00. On average, they expect Intellia Therapeutics' stock price to reach $26.80 in the next year. View Analyst Ratings for Intellia Therapeutics.
What are analysts saying about Intellia Therapeutics stock?
Here are some recent quotes from research analysts about Intellia Therapeutics stock:
- 1. Cann analysts commented, "Loss per share was $0.45 compared to our estimated loss of $0.39. This was the result of lower than expected Collaborative revenue of $5.9 million compared to our estimate of $6.5 million and higher than estimated R&D expenses of $15.6 million compared to our estimated $14.1 million. Lower revenue and higher expenses were partially offset by a higher than estimated shares outstanding. There were no other meaningful variances in the quarter. Our outlook remains basically unchanged. We have made modest adjustments to our estimated shares outstanding and R&D expense." (8/1/2017)
- 2. According to Zacks Investment Research, "Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2017)
- 3. Chardan Capital analysts commented, "We initiate coverage of Intellia Therapeutics (NTLA) with a Buy rating (PT $19), on our view of possible downside driven by the company's IP weakness overridden by relative under-valuation of the CRISPR sector. Intellia is a preclinical biotech company aiming to treat various genetic conditions using the CRISPR-Cas9 gene editing system, in which a CRISPR guide RNA (gRNA) targets a Cas9 nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Intellia's lead asset for transthyretin (TTR) amyloidosis, partnered with Neutral-rated Regeneron Pharmaceuticals, is guided to initiate IND-enabling studies by 2H17/1H18." (3/27/2017)
Who are some of Intellia Therapeutics' key competitors?
Some companies that are related to Intellia Therapeutics include Medpace Holdings (MEDP), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Global Blood Therapeutics (GBT), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Immunomedics (IMMU), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Albany Molecular Research (AMRI), Cellectis S.A. (CLLS), BeyondSpring (BYSI), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Crispr Theraptc (CRSP), Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX) and ImmunoGen (IMGN).
Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the folowing people:
- Perry A. Karsen, Chairman of the Board
- Nessan Bermingham, President, Chief Executive Officer, Founder, Director
- Graeme Bell, Chief Financial Officer, Executive Vice President
- Jose E. Rivera J.D., Executive Vice President, General Counsel
- John M. Leonard M.D., Executive Vice President - Research and Development
- Frank Verwiel M.D., Director
- Caroline D. Dorsa, Independent Director
- Jean-Francois Formela M.D., Independent Director
- Carl L. Gordon Ph.D., Independent Director
When did Intellia Therapeutics IPO?
(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who owns Intellia Therapeutics stock?
Intellia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Atlas Venture Associates IX LLC (10.35%), FMR LLC (8.94%), Vanguard Group Inc. (2.76%), Artal Group S.A. (0.69%), ARK Investment Management LLC (0.48%) and State Street Corp (0.46%). Company insiders that own Intellia Therapeutics stock include Bros Advisors Lp Baker, Carl L Gordon, Institutes For Biomed Novartis, Jean Francois Formela and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.
Who sold Intellia Therapeutics stock? Who is selling Intellia Therapeutics stock?
Intellia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, Northern Trust Corp, Acadian Asset Management LLC and ProShare Advisors LLC. Company insiders that have sold Intellia Therapeutics stock in the last year include Jean Francois Formela and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Intellia Therapeutics.
Who bought Intellia Therapeutics stock? Who is buying Intellia Therapeutics stock?
Intellia Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Vanguard Group Inc., OxFORD Asset Management LLP, GSA Capital Partners LLP, State Street Corp, TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP and American Century Companies Inc.. Company insiders that have bought Intellia Therapeutics stock in the last two years include Bros Advisors Lp Baker, Carl L Gordon and Institutes For Biomed Novartis. View Insider Buying and Selling for Intellia Therapeutics.
How do I buy Intellia Therapeutics stock?
Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intellia Therapeutics' stock price today?
MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Intellia Therapeutics stock can currently be purchased for approximately $17.43.
Consensus Ratings for Intellia Therapeutics (NASDAQ:NTLA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$26.80 (53.76% upside)|
Analysts' Ratings History for Intellia Therapeutics (NASDAQ:NTLA)
(Data available from 8/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/2/2017||Chardan Capital||Reiterated Rating||Buy||$19.00 -> $20.00||Low|
|7/22/2017||Jefferies Group LLC||Reiterated Rating||Buy||$36.00||High|
|7/18/2017||Oppenheimer Holdings, Inc.||Initiated Coverage||Market Perform||High|
|6/3/2017||Credit Suisse Group||Set Price Target||Buy||$24.00||Low|
|1/5/2017||Leerink Swann||Reiterated Rating||Outperform||N/A|
|9/28/2016||Janney Montgomery Scott||Initiated Coverage||Buy||$29.00||N/A|
Earnings History for Intellia Therapeutics (NASDAQ:NTLA)Earnings History by Quarter for Intellia Therapeutics (NASDAQ NTLA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||($0.42)||($0.45)||$5.83 million||$5.90 million||View||N/A|
|5/2/2017||Q1 2017||($0.34)||($0.36)||$5.30 million||$6.22 million||View||N/A|
|3/14/2017||Q4 2016||($0.21)||($0.31)||$5.63 million||$5.63 million||View||N/A|
|11/1/2016||Q3 2016||($0.22)||($0.22)||$4.55 million||$4.90 million||View||N/A|
|8/4/2016||Q2 2016||($0.10)||($0.36)||$6.34 million||$4.21 million||View||N/A|
Earnings Estimates for Intellia Therapeutics (NASDAQ:NTLA)
2017 EPS Consensus Estimate: ($1.67)
2018 EPS Consensus Estimate: ($1.95)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Intellia Therapeutics (NASDAQ:NTLA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Intellia Therapeutics (NASDAQ:NTLA)
Insider Ownership Percentage: 12.80%Insider Trades by Quarter for Intellia Therapeutics (NASDAQ:NTLA)
Institutional Ownership Percentage: 47.20%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/11/2017||Venture Fund Ix L.P. Atlas||Major Shareholder||Sell||150,000||$16.24||$2,436,000.00|| |
|3/10/2017||Jean Francois Formela||Director||Sell||21,132||$13.91||$293,946.12|| |
|5/11/2016||Bros. Advisors Lp Baker||Insider||Buy||200,000||$18.00||$3,600,000.00|| |
|5/11/2016||Carl L Gordon||Director||Buy||250,000||$18.00||$4,500,000.00|| |
|5/11/2016||Institutes For Biomed Novartis||Major Shareholder||Buy||277,777||$18.00||$4,999,986.00|| |
Headline Trends for Intellia Therapeutics (NASDAQ:NTLA)
Latest Headlines for Intellia Therapeutics (NASDAQ:NTLA)
|Investors: Covered-call reports for Box, Foot Locker, Fabrinet, Intellia Therapeutics and Tenet Healthcare|
www.prnewswire.com - August 23 at 9:27 AM
|Intellia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : NTLA-US : August 22, 2017|
finance.yahoo.com - August 23 at 9:27 AM
|Zacks: Analysts Anticipate Intellia Therapeutics, Inc. (NTLA) Will Post Quarterly Sales of $5.83 Million|
www.americanbankingnews.com - August 18 at 3:02 AM
|Intellia Therapeutics, Inc. (NTLA) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - August 15 at 11:56 AM
|Former GSK exec resigns from Intellia board due to 'conflict' - Boston Business Journal|
www.bizjournals.com - August 11 at 7:00 AM
|Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher - TheStreet.com|
www.thestreet.com - August 9 at 5:32 AM
|Intellia Therapeutics, Inc. (NTLA) to Post Q3 2017 Earnings of ($0.54) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - August 4 at 7:16 AM
|Q3 2017 EPS Estimates for Intellia Therapeutics, Inc. Lowered by Wedbush (NASDAQ:NTLA)|
www.americanbankingnews.com - August 4 at 7:12 AM
|Leerink Swann Brokers Lower Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA)|
www.americanbankingnews.com - August 3 at 7:58 AM
|Q3 2017 EPS Estimates for Intellia Therapeutics, Inc. Increased by Oppenheimer Holdings (NTLA)|
www.americanbankingnews.com - August 3 at 7:58 AM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Buy Rating at Chardan Capital|
www.americanbankingnews.com - August 2 at 2:02 PM
| Intellia Therapeutics Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 2 at 6:26 AM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Announces Earnings Results, Misses Estimates By $0.03 EPS|
www.americanbankingnews.com - August 1 at 2:20 PM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Earns Hold Rating from Cann|
www.americanbankingnews.com - August 1 at 12:56 PM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Expected to Post Quarterly Sales of $5.83 Million|
www.americanbankingnews.com - July 31 at 9:22 AM
|Intellia Therapeutics, Inc. (NTLA) Expected to Post Earnings of -$0.41 Per Share|
www.americanbankingnews.com - July 29 at 4:20 PM
|Intellia Therapeutics (NTLA) Appoints Moncef Slaoui and Frank Verweil to Board - StreetInsider.com|
www.streetinsider.com - July 27 at 5:31 AM
|Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee|
finance.yahoo.com - July 25 at 6:16 AM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Earns Buy Rating from Jefferies Group LLC|
www.americanbankingnews.com - July 22 at 1:32 PM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - July 21 at 9:10 AM
|Q2 2017 Earnings Forecast for Intellia Therapeutics, Inc. Issued By Oppenheimer Holdings (NASDAQ:NTLA)|
www.americanbankingnews.com - July 20 at 8:06 AM
|Biotech Forum Daily Digest: Update On Approximately $5 Cytosorbents|
seekingalpha.com - July 19 at 12:28 AM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - July 18 at 2:20 PM
|Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Market Perform Rating from Cann|
www.americanbankingnews.com - July 17 at 7:44 PM
|Venture Fund Ix L.P. Atlas Sells 150,000 Shares of Intellia Therapeutics, Inc. (NTLA) Stock|
www.americanbankingnews.com - July 11 at 7:53 PM
|Intellia Therapeutics, Inc. (NTLA) Stock Rating Upgraded by TheStreet|
www.americanbankingnews.com - July 11 at 11:54 AM
|Intellia Therapeutics, Inc. (NTLA) Expected to Post Quarterly Sales of $5.61 Million|
www.americanbankingnews.com - July 7 at 1:26 PM
|-$0.42 EPS Expected for Intellia Therapeutics, Inc. (NTLA) This Quarter|
www.americanbankingnews.com - July 5 at 1:08 PM
|Intellia Therapeutics Inc (NTLA) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - June 26 at 8:54 AM
|Jefferies Group Comments on Intellia Therapeutics Inc's Q2 2017 Earnings (NTLA)|
www.americanbankingnews.com - June 26 at 7:10 AM
|Intellia Therapeutics, Inc. – Value Analysis (NASDAQ:NTLA) : June 22, 2017|
finance.yahoo.com - June 23 at 8:34 AM
|Intellia Therapeutics Inc (NTLA) Earns Buy Rating from Analysts at Jefferies Group LLC|
www.americanbankingnews.com - June 22 at 11:02 AM
|Intellia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : NTLA-US : June 20, 2017|
finance.yahoo.com - June 20 at 8:01 PM
|Intellia Therapeutics (NTLA) Receives Patent for CRISPR/Cas Genome Editing in China - StreetInsider.com|
www.streetinsider.com - June 19 at 11:02 AM
|Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China|
finance.yahoo.com - June 19 at 11:02 AM
|Intellia Therapeutics Inc (NTLA) Expected to Announce Quarterly Sales of $5.30 Million|
www.americanbankingnews.com - June 11 at 9:20 AM
|-$0.41 Earnings Per Share Expected for Intellia Therapeutics Inc (NTLA) This Quarter|
www.americanbankingnews.com - June 9 at 10:22 AM
|Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer|
finance.yahoo.com - June 6 at 8:37 AM
|Regeneron Announces Positive Data on Carcinoma Candidate - Nasdaq|
www.nasdaq.com - June 6 at 12:39 AM
|Intellia Therapeutics Inc (NTLA) PT Set at $24.00 by Credit Suisse Group AG|
www.americanbankingnews.com - June 4 at 11:46 PM
|Intellia Therapeutics Inc (NTLA) Short Interest Update|
www.americanbankingnews.com - June 4 at 11:34 AM
|Intellia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : NTLA-US : May 26, 2017|
finance.yahoo.com - May 26 at 7:52 PM
|Intellia Therapeutics' (NTLA) "Outperform" Rating Reiterated at Wedbush|
www.americanbankingnews.com - May 15 at 9:34 PM
|Intellia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : NTLA-US : May 15, 2017|
finance.yahoo.com - May 15 at 10:07 AM
|Zacks: Analysts Expect Intellia Therapeutics Inc (NTLA) Will Announce Earnings of -$0.41 Per Share|
www.americanbankingnews.com - May 15 at 10:00 AM
|Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting|
finance.yahoo.com - May 14 at 10:41 AM
|Q2 2017 EPS Estimates for Intellia Therapeutics Inc Reduced by Leerink Swann (NTLA)|
www.americanbankingnews.com - May 5 at 7:16 AM
|Q2 2017 EPS Estimates for Intellia Therapeutics Inc Cut by Wedbush (NTLA)|
www.americanbankingnews.com - May 5 at 7:16 AM
|Research Analysts Issue Forecasts for Intellia Therapeutics Inc's Q1 2018 Earnings (NTLA)|
www.americanbankingnews.com - May 4 at 5:50 PM
|Intellia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : NTLA-US : May 4, 2017|
finance.yahoo.com - May 4 at 11:18 AM
Intellia Therapeutics (NTLA) Chart for Thursday, August, 24, 2017